When was Affinium Pharmaceuticals founded?

Affinium Pharmaceuticals was founded in 2000 and raised its 1st funding round 7 years after it was founded.

Where is Affinium Pharmaceuticals located?

Affinium Pharmaceuticals is headquartered in Toronto, Canada.

Is Affinium Pharmaceuticals a funded company?

Affinium Pharmaceuticals is a funded company, having raised a total of $33M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 26, 2007.

When was the latest funding round of Affinium Pharmaceuticals?

Affinium Pharmaceuticals' latest funding was a $***** Conventional Debt round on Sep 09, 2013, with participation from 0 investor. Its primary sector is Infectious Diseases. Globally, the Infectious Diseases sector has seen $1.49B in funding in 2026 to date.

Where does Affinium Pharmaceuticals rank among its competitors?

Affinium Pharmaceuticals ranks 103rd amongst 212 active competitors, of which 77 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured $60M in Aug, 2026.

Who are the top competitors of Affinium Pharmaceuticals?

Affinium Pharmaceuticals' top competitors include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Among them, Vedanta Biosciences secured the most recent funding round in August, 2026.

Affinium Pharmaceuticals - 2026 Company Profile, Funding & Competitors

Affinium Pharmaceuticals is an acqui-hired company based in Toronto (Canada), founded in 2000. It operates as a Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm. Affinium Pharmaceuticals has raised $33M in funding from Forward Ventures and Ontario Capital Growth Corporation. The company has 212 active competitors, including 77 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.

Company Details

Affinium Pharmaceuticals was a Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. As of February 11, 2014, Affinium Pharmaceuticals was acquired by Debiopharm Group. The company has a proprietary antibacterial platform that targets bacterial fatty acid synthesis. The company was developing AFN-1252, and its pro-drug, AFN-1720 for the oral and IV treatment of staphylococcal infections (tested on 5400 strains), including methicillin-resistant S. aureus (MRSA), and vancomycin-intermediate S. aureus (VISA). At the time of acquisition, AFN-1252 had completed a Phase 2a study for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and AFN-1720 was in Phase 1 clinical development. Affinium was previously called Integrative Proteomics, Inc.

Website: afnm.com
Part Of

Key Metrics

Founded Year

2000

Location

Toronto, Canada

Stage

Acqui-Hired

Total Funding

$33M in 3 rounds

Latest Funding Round

Conventional Debt, Sep 09, 2013, $*****

Investors

Forward Ventures & 4 more

Ranked

103^rd among 212 active competitors

Similar Companies

Spero Therapeutics & 264 more

View Affinium Pharmaceuticals' full profile

Affinium Pharmaceuticals has raised a total funding of $33M over 3 rounds. Its first funding round was on Mar 26, 2007. Affinium Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Affinium Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 09, 2013	1089097	Conventional Debt	4773447	5970931	4183356	4032401
Aug 30, 2011	5676348	Series B	9392400	7319313	6434050	Forward Ventures & 2 more
Mar 26, 2007	5800291	Series A	6588921	2358948	Forward Ventures	Oxford Bioscience Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Affinium Pharmaceuticals's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Affinium Pharmaceuticals include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of Affinium Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	69/100
2nd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
3rd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	63/100
4th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Phase4 Partners, Athyrium Capital Management ... & 25 others	61/100
5th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	Hillhouse, RA Capital Management & 12 others	61/100
7th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
8th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	60/100
9th	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$410M	Invesco, Seventure Partners & 40 others	59/100
10th	smartbax 2021, Munich (Germany), Seed	Developer of multi-targeted antibacterial compounds	$7.51M	Anobis Asset, Bayern Kapital & 4 others	59/100
103rd	Affinium Pharmaceuticals 2000, Toronto (Canada), Acqui-Hired	Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. Acquired by Debiopharm	$33M	Ontario Capital Growth Corporation, Genesys Capital ... & 3 others	32/100